.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The IMPACT randomized trial compared once-daily triple therapy with two dual-combination inhaler regimens in patients with symptomatic moderate-to-severe COPD and a history of exacerbations. Triple therapy reduced the annual rate of moderate or severe COPD exacerbations and improved lung function and health status compared with selected dual therapies. The study is clinically relevant to general physicians because COPD care often involves balancing symptom burden, exacerbation risk, inhaler complexity and adverse effects. Inhaled corticosteroid-containing regimens may be particularly useful for patients with frequent exacerbations or features suggesting an eosinophilic phenotype, but treatment should be individualized. Correct inhaler technique and adherence are as important as selecting the pharmacologic combination. The evidence also demonstrates why COPD management should include vaccination, smoking cessation, pulmonary rehabilitation and comorbidity assessment rather than treating inhaler prescriptions as the entire intervention. For APICON's obstructive-airway focus, IMPACT provides a practical example of how evidence from controlled trials can be translated into phenotype-based escalation while avoiding unnecessary treatment in lower-risk patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The IMPACT randomized trial compared once-daily triple therapy with two dual-combination inhaler regimens in patients with symptomatic moderate-to-severe COPD and a history of exacerbations. Triple therapy reduced the annual rate of moderate or severe COPD exacerbations and improved lung function and health status compared with selected dual therapies. The study is clinically relevant to general physicians because COPD care often involves balancing symptom burden, exacerbation risk, inhaler complexity and adverse effects. Inhaled corticosteroid-containing regimens may be particularly useful for patients with frequent exacerbations or features suggesting an eosinophilic phenotype, but treatment should be individualized. Correct inhaler technique and adherence are as important as selecting the pharmacologic combination. The evidence also demonstrates why COPD management should include vaccination, smoking cessation, pulmonary rehabilitation and comorbidity assessment rather than treating inhaler prescriptions as the entire intervention. For APICON's obstructive-airway focus, IMPACT provides a practical example of how evidence from controlled trials can be translated into phenotype-based escalation while avoiding unnecessary treatment in lower-risk patients.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
